An innately interesting decade of research in immunology

Nature Medicine

Volumn 10, Issue 12, 2004, Pages 1307-1320

  Germain, Ronald N ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE DEAMINASE; NATURAL KILLER CELL RECEPTOR NKG2D; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR;

ANTIGEN SPECIFICITY; CELL FUNCTION; CELL SUBPOPULATION; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE SEQUENCE; HISTORY OF MEDICINE; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOREACTIVITY; IMMUNOREGULATION; MEDICAL RESEARCH; MUTATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SEQUENCE HOMOLOGY; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ALLERGY AND IMMUNOLOGY; APOPTOSIS; DENDRITIC CELLS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; IMMUNITY, NATURAL; KILLER CELLS, NATURAL; MEMBRANE GLYCOPROTEINS; MODELS, IMMUNOLOGICAL; PORTRAITS; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 11144340471     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1159     Document Type: Review

References (298)

1. Shaw, G.B. The Doctor's Dilemma http://www.webbooks.com/Classics/ Nonfiction/Drama/Shaw/Doctor/Home.htm
2. Metchnikoff, I.I. On the Present State of the Question of Immunity in Infectious Diseases. (1908). http://nobelprize.org/medicine/laureates/1908/ mechnikov-lecture.html
3. Ehrlich, P. Partial Cell Functions (lecture, 1908). in Nobel Lectures, Physiology or Medicine 1901-1921. (Elsevier Publishing Company, Amsterdam, 1967).
4. Edelman, G.M. et al. The covalent structure of an entire γG immunoglobulin molecule. Proc. Natl. Acad. Sci. USA 63, 78-85 (1969).
5. Davies, D.R., Padlan, E.A. & Segal, D.M. Three-dimensional structure of immunoglobulins. Annu. Rev. Biochem. 44, 639-667 (1975).
6. Amzel, L.M. & Poljak, R.J. Three-dimensional structure of immunoglobulins. Annu. Rev. Biochem. 48, 961-997 (1979).
7. Bjorkman, P.J. et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329, 506-512 (1987).
8. Brack, C., Hirama, M., Lenhard-Schuller, R. & Tonegawa, S. A complete immunoglobulin gene is created by somatic recombination. Cell 15, 1-14 (1978).
9. Hedrick, S.M., Cohen, D.I., Nielsen, E.A. & Davis, M.M. Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature 308, 149-153 (1984).
10. Yanagi, Y. et al. A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains. Nature 308, 145-149 (1984).
11. Benacerraf, B. & McDevitt, H.O. Histocompatibility-linked immune response genes. Science 175, 273-279 (1972).
12. Rosenthal, A.S. & Shevach, E.M. Function of macrophages in antigen recognition by guinea pig T lymphocytes. I. Requirement for histocompatible macrophages and lymphocytes. J. Exp. Med. 138, 1194-1212 (1973).
13. Zinkernagel, R.M. & Doherty, P.C. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248, 701-702 (1974).
14. Townsend, A.R., Gotch, F.M. & Davey, J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 42, 457-467 (1985).
15. Babbitt, B.P., Allen, P.M., Matsueda, G., Haber, E. & Unanue, E.R. Binding of immunogenic peptides to Ia histocompatibility molecules. Nature 317, 359-361 (1985).
16. Heber-Katz, E., Hansburg, D. & Schwartz, R.H. The Ia molecule of the antigen-presenting cell plays a critical role in immune response gene regulation of T cell activation. J. Mol. Cell. Immunol. 1, 3-18 (1983).
17. Buus, S., Sette, A., Colon, S.M., Miles, C. & Grey, H.M. The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science 235, 1353-1358 (1987).
18. Stern, L.J. & Wiley, D.C. Antigenic peptide binding by class I and class II histocompatibility proteins. Structure 2, 245-251 (1994).
19. Germain, R.N. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76, 287-299 (1994).
20. Hesslein, D.G. & Schatz, D.G. Factors and forces controlling V(D)J recombination. Adv. Immunol. 78, 169-232 (2001).
21. Jung, D. & Alt, F.W. Unraveling V(D)J recombination; insights into gene regulation. Cell 116, 299-311 (2004).
22. Honjo, T., Muramatsu, M. & Fagarasan, S. AID: how does it aid antibody diversity? Immunity 20, 659-668 (2004).
23. Dorfman, J.R. & Germain, R.N. MHC-dependent survival of naive T cells? A complicated answer to a simple question. Microbes Infect. 4, 547-554 (2002).
24. Wulfing, C. et al. Costimulation and endogenous MHC ligands contribute to T cell recognition. Nat. Immunol. 3, 42-47 (2002).
25. Stefanova, I., Dorfman, J.R. & Germain, R.N. Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature 420, 429-434 (2002).
26. Germain, R.N. & Stefanova, I. The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu. Rev. Immunol. 17, 467-522 (1999).
27. Krummel, M., Wulfing, C., Sumen, C. & Davis, M.M. Thirty-six views of T-cell recognition. Phil. Trans. R. Soc. Lond. B Biol. Sci. 355, 1071-1076 (2000).
28. Janeway, C.A., Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 1, 1-13 (1989).
29. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045 (1994).
30. Medzhitov, R., Preston-Hurlburt, P. & Janeway, C.A., Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-397 (1997).
31. Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085-2088 (1998).
32. Hoffmann, J.A. The immune response of Drosophila. Nature 426, 33-38 (2003).
33. Ferrandon, D., Imler, J.L. & Hoffmann, J.A. Sensing infection in Drosophila: Toll and beyond. Semin. Immunol. 16, 43-53 (2004).
34. Ganz, T. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3, 710-720 (2003).
35. Takeda, K., Kaisho, T. & Akira, S. Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2003).
36. Rutz, M. et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur. J. Immunol. 34, 2541-2550 (2004).
37. Beutler, B., Hoebe, K., Du, X. & Ulevitch, R.J. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J. Leukoc. Biol. 74, 479-485 (2003).
38. Janssens, S. & Beyaert, R. Role of Toll-like receptors in pathogen recognition. Clin. Microbiol. Rev. 16, 637-646 (2003).
39. Kapsenberg, M.L. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 3, 984-993 (2003).
40. Reis e Sousa, C. Toll-like receptors and dendritic cells: for whom the bug tolls. Semin. Immunol. 16, 27-34 (2004).
41. Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987-995 (2004).
42. Beutler, B. Not "molecular patterns" but molecules. Immunity 19, 155-156 (2003).
43. Medzhitov, R. & Janeway, C.A., Jr. Innate immunity. N. Engl. J. Med. 343, 338-344 (2000).
44. Barton, G.M. & Medzhitov, R. Toll-like receptor signaling pathways. Science 300, 1524-1525 (2003).
45. Beutler, B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430, 257-263 (2004).
46. Vogel, S.N., Fitzgerald, K.A. & Fenton, M.J. TLRs: differential adapter utilization by toll-like receptors mediates TLR-specific patterns of gene expression. Mol. Interv. 3, 466-477 (2003).
47. Beutler, B., Hoebe, K. & Shamel, L. Forward genetic dissection of afferent immunity: the role of TIR adapter proteins in innate and adaptive immune responses. C. R. Biol. 327, 571-580 (2004).
48. Weighardt, H. et al. Identification of a TLR4- and TRIF-dependent activation program of dendritic cells. Eur. J. Immunol. 34, 558-564 (2004).
49. Beutler, B. & Poltorak, A. Sepsis and evolution of the innate immune response. Crit. Care Med. 29, S2-6; discussion S6-7 (2001).
50. Cristofaro, P. & Opal, S.M. The Toll-like receptors and their role in septic shock. Expert Opin. Ther. Targets 7, 603-612 (2003).
51. Steinman, R.M. & Cohn, Z.A. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 137, 1142-1162 (1973).
52. Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
53. Liu, Y.J. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 106, 259-262 (2001).
54. Fazekas De St Groth, B. et al. Experimental models linking dendritic cell lineage, phenotype and function. Immunol. Cell Biol. 80, 469-476 (2002).
55. Ardavin, C. Origin, precursors and differentiation of mouse dendritic cells. Nat. Rev. Immunol. 3, 582-590 (2003).
56. Wilson, H.L. & O'Neill, H.C. Murine dendritic cell development: difficulties associated with subset analysis. Immunol. Cell Biol. 81, 239-246 (2003).
57. Kadowaki, N. et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194, 863-869 (2001).
58. Jarrossay, D., Napolitani, G., Colonna, M., Sallusto, F. & Lanzavecchia, A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol. 31, 3388-3393 (2001).
59. + DC correlates with unresponsiveness to imidazoquinolines. Eur. J. Immunol. 33, 827-833 (2003).
60. Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A. & Coffman, R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136, 2348-2357 (1986).
61. Mosmann, T.R. & Coffman, R.L. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv. Immunol. 46, 111-147 (1989).
62. + T cells. Annu. Rev. Immunol. 12, 635-673 (1994).
63. Sacks, D. & Noben-Trauth, N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2, 845-858 (2002).
64. H2 paradigm. Nat. Rev. Immunol. 4, 583-594 (2004).
65. H1 lineage commitment. Cell 100, 655-669 (2000).
66. H2 cytokine gene expression in CD4 T cells. Cell 89, 587-596 (1997).
67. H1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity 9, 745-755 (1998).
68. Pulendran, B. et al. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J. Immunol. 167, 5067-5076 (2001).
69. Pulendran, B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 199, 227-250 (2004).
70. Leadbetter, E.A. et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416, 603-607 (2002).
71. Marshak-Rothstein, A., Busconi, L., Rifkin, I.R. & Viglianti, G.A. The stimulation of Toll-like receptors by nuclear antigens: a link between apoptosis and autoimmunity. Rheum. Dis. Clin. North Am. 30, 559-74, ix (2004).
72. Ahmad-Nejad, P. et al. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32, 1958-1968 (2002).
73. Tsan, M.F. & Gao, B. Endogenous ligands of Toll-like receptors. J. Leukoc. Biol. 76, 514-519 (2004).
74. Geijtenbeek, T.B., Engering, A. & Van Kooyk, Y. DC-SIGN, a C-type lectin on dendritic cells that unveils many aspects of dendritic cell biology. J. Leukoc. Biol. 71, 921-931 (2002).
75. Gordon, S. Pattern recognition receptors: doubling up for the innate immune response. Cell 111, 927-930 (2002).
76. Diebold, S.S. et al. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 424, 324-328 (2003).
77. Santini, S.M. et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 191, 1777-1788 (2000).
78. Reid, S.D., Penna, G. & Adorini, L. The control of T cell responses by dendritic cell subsets. Curr. Opin. Immunol. 12, 114-121 (2000).
79. Liu, Y.J., Kanzler, H., Soumelis, V. & Gilliet, M. Dendritic cell lineage, plasticity and cross-regulation. Nat. Immunol. 2, 585-589 (2001).
80. H2 responses with microbes, dendritic cells, and pathogen recognition receptors. Immunol. Res. 29, 187-196 (2004).
81. Lotze, M.T. & Thomson, A.W. (eds.). Dendritic Cells: Biology and Clinical Applications (Academic, San Diego, 1999).
82. Traver, D. et al. Development of CD8α-positive dendritic cells from a common myeloid progenitor. Science 290, 2152-2154 (2000).
83. Manz, M.G., Traver, D., Miyamoto, T., Weissman, I.L. & Akashi, K. Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood 97, 3333-3341 (2001).
84. Wu, L. et al. Development of thymic and splenic dendritic cell populations from different hemopoietic precursors. Blood 98, 3376-3382 (2001).
85. Kamath, A.T. et al. The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J. Immunol. 165, 6762-6770 (2000).
86. + mouse spleen dendritic cells do not originate from the CD8α - dendritic cell subset. Blood 102, 601-604 (2003).
87. Tsujimura, H. et al. ICSBP/IRF-8 retrovirus transduction rescues dendritic cell development in vitro. Blood 101, 961-969 (2003).
88. Aliberti, J. et al. Essential role for ICSBP in the in vivo development of murine CD8α+ dendritic cells. Blood 101, 305-310 (2003).
89. Siegal, F.P. et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 284, 1835-1837 (1999).
90. Kadowaki, N., Antonenko, S., Lau, J.Y. & Liu, Y.J. Natural interferon α/β -producing cells link innate and adaptive immunity. J. Exp. Med. 192, 219-226 (2000).
91. Asselin-Paturel, C. et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat. Immunol. 2, 1144-1150 (2001).
92. Dalod, M. et al. Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta. J. Exp. Med. 197, 885-898 (2003).
93. LeibundGut-Landmann, S., Waldburger, J.M., Reis e Sousa, C., Acha-Orbea, H. & Reith, W. MHC class II expression is differentially regulated in plasmacytoid and conventional dendritic cells. Nat. Immunol. 5, 899-908 (2004).
94. Rissoan, M.C. et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283, 1183-1186 (1999).
95. H2 and nonpolarized T cells. Nat. Immunol. 1, 311-316 (2000).
96. Penna, G., Vulcano, M., Sozzani, S. & Adorini, L. Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells. Hum. Immunol. 63, 1164-1171 (2002).
97. Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745 (2000).
98. Hemmi, H., Kaisho, T., Takeda, K. & Akira, S. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J. Immunol. 170, 3059-3064 (2003).
99. Krieg, A.M. & Davis, H.L. Enhancing vaccines with immune stimulatory CpG DNA. Curr. Opin. Mol. Ther. 3, 15-24 (2001).
100. Krieg, A.M., Yi, A.K., Schorr, J. & Davis, H.L. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 6, 23-27 (1998).
101. Pisetsky, D.S. Mechanisms of immune stimulation by bacterial DNA. Springer Semin. Immunopathol. 22, 21-33 (2000).
102. Jahnsen, F.L., Farkas, L., Lund-Johansen, F. & Brandtzaeg, P. Involvement of plasmacytoid dendritic cells in human diseases. Hum. Immunol. 63, 1201-1205 (2002).
103. de Heer, H.J. et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J. Exp. Med. 200, 89-98 (2004).
104. Steinman, R.M. & Nussenzweig, M.C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA 99, 351-358 (2002).
105. Lu, L. & Thomson, A.W. Manipulation of dendritic cells for tolerance induction in transplantation and autoimmune disease. Transplantation 73, S19-S22 (2002).
106. Steinman, R.M., Hawiger, D. & Nussenzweig, M.C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685-711 (2003).
107. von Boehmer, H., Teh, H.S. & Kisielow, P. The thymus selects the useful, neglects the useless and destroys the harmful. Immunol. Today 10, 57-61 (1989).
108. Heath, V.L., Moore, N.C., Parnell, S.M. & Mason, D.W. Intrathymic expression of genes involved in organ specific autoimmune disease. J. Autoimmun. 11, 309-318 (1998).
109. Heino, M. et al. Autoimmune regulator is expressed in the cells regulating immune tolerance in thymus medulla. Biochem. Biophys. Res. Commun. 257, 821-825 (1999).
110. Derbinski, J., Schulte, A., Kyewski, B. & Klein, L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat. Immunol. 2, 1032-1039 (2001).
111. Anderson, M.S. et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 298, 1395-1401 (2002).
112. Liston, A., Lesage, S., Wilson, J., Peltonen, L. & Goodnow, C.C. Aire regulates negative selection of organ-specific T cells. Nat. Immunol. 4, 350-354 (2003).
113. Kyewski, B. & Derbinski, J. Self-representation in the thymus: an extended view. Nat. Rev. Immunol. 4, 688-698 (2004).
114. Scott, H.S. et al. Common mutations in autoimmune polyendocrinopathy- candidiasis-ectodermal dystrophy patients of different origins. Mol. Endocrinol. 12, 1112-1119 (1998).
115. Rosatelli, M.C. et al. A common mutation in Sardinian autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. Hum. Genet. 103, 428-434 (1998).
116. Liston, A. et al. Gene dosage-limiting role of Aire in thymic expression, clonal deletion, and organ-specific autoimmunity. J. Exp. Med. 200, 1015-1026 (2004).
117. Hornum, L. & Markholst, H. New autoimmune genes and the pathogenesis of type 1 diabetes. Curr. Diab. Rep. 4, 135-142 (2004).
118. + T Cells. J. Exp. Med. 186, 239-245 (1997).
119. Steinman, R.M., Turley, S., Mellman, I. & Inaba, K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 191, 411-416 (2000).
120. Heath, W.R. & Carbone, F.R. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19, 47-64 (2001).
121. Hawiger, D. et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769-779 (2001).
122. + T cell tolerance. J. Exp. Med. 196, 1627-1638 (2002).
123. Legge, K.L. et al. On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity. J. Exp. Med. 196, 217-227 (2002).
124. Stockinger, B. & Hausmann, B. Functional recognition of in vivo processed self antigen. Int. Immunol. 6, 247-254 (1994).
125. Huang, F.P. et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J. Exp. Med. 191, 435-444 (2000).
126. Scheinecker, C., McHugh, R., Shevach, E.M. & Germain, R.N. Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J. Exp. Med. 196, 1079-1090 (2002).
127. Min, W.P. et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J. Immunol. 170, 1304-1312 (2003).
128. + regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198, 235-247 (2003).
129. Fisson, S. et al. Continuous activation of autoreactive CD4+CD25+ regulatory T cells in the steady state. J. Exp. Med. 198, 737-746 (2003).
130. Steinman, R.M. et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann NY Acad Sci 987, 15-25 (2003).
131. Inaba, K. et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176, 1693-1702 (1992).
132. Maraskovsky, E. et al. Dramatic numerical increase of functionally mature dendritic cells in FLT3 ligand-treated mice. Adv. Exp. Med. Biol. 417, 33-40 (1997).
133. Young, J.W. Dendritic cells: expansion and differentiation with hematopoietic growth factors. Curr. Opin. Hematol. 6, 135-144 (1999).
134. Zou, G.M. & Tam, Y.K. Cytokines in the generation and maturation of dendritic cells: recent advances. Eur. Cytokine Netw. 13, 186-199 (2002).
135. Steinman, R.M. & Dhodapkar, M. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 94, 459-473 (2001).
136. Schuler, G., Schuler-Thurner, B. & Steinman, R.M. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15, 138-147 (2003).
137. Figdor, C.G., de Vries, I.J., Lesterhuis, W.J. & Melief, C.J. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10, 475-480 (2004).
138. Carayanniotis, G., Skea, D.L., Luscher, M.A. & Barber, B.H. Adjuvant-independent immunization by immunotargeting antigens to MHC and non-MHC determinants in vivo. Mol. Immunol. 28, 261-267 (1991).
139. Finkelman, F.D., Lees, A., Birnbaum, R., Gause, W.C. & Morris, S.C. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J. Immunol. 157, 1406-1414 (1996).
140. van Bergen, J. et al. Get into the groove! Targeting antigens to MHC class II. Immunol. Rev. 172, 87-96 (1999).
141. Kiessling, R., Klein, E. & Wigzell, H. Natural killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol. 5, 112-117 (1975).
142. Kiessling, R. & Haller, O. Natural killer cells in the mouse: an alternative immune surveillance mechanism? Contemp. Top. Immunobiol. 8, 171-201 (197B).
143. Herberman, R.B. & Holden, H.T. Natural cell-mediated immunity. Adv. Cancer Res. 27, 305-377 (197B).
144. Karlhofer, F.M., Ribaudo, R.K. & Yokoyama, W.M. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 358, 66-70 (1992).
145. Moretta, A. et al. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Antip58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J. Exp. Med. 178, 597-604 (1993).
146. Litwin, V., Gumperz, J., Parham, P., Phillips, J.H. & Lanier, L.L. NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J. Exp. Med. 180, 537-543 (1994).
147. Daniels, B.F., Karlhofer, F.M., Seaman, W.E. & Yokoyama, W.M. A natural killer cell receptor specific for a major histocompatibility complex class I molecule. J. Exp. Med. 180, 687-692 (1994).
148. Brennan, J., Mager, D., Jefferies, W. & Takei, F. Expression of different members of the Ly-49 gene family defines distinct natural killer cell subsets and cell adhesion properties. J. Exp. Med. 180, 2287-2295 (1994).
149. Wagtmann, N. et al. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra-and intracellular domains. Immunity 2, 439-449 (1995).
150. Lanier, L.L. NK cell receptors. Annu. Rev. Immunol. 16, 359-393 (1998).
151. Yokoyama, W.M. & Plougastel, B.F. Immune functions encoded by the natural killer gene complex. Nat. Rev. Immunol. 3, 304-316 (2003).
152. Raulet, D.H. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3, 781-790 (2003).
153. Bottino, C., Moretta, L., Pende, D., Vitale, M. & Moretta, A. Learning how to discriminate between friends and enemies, a lesson from Natural Killer cells. Mol. Immunol. 41, 569-575 (2004).
154. Raulet, D.H., Vance, R.E. & McMahon, C.W. Regulation of the natural killer cell receptor repertoire. Annu. Rev. Immunol. 19, 291-330 (2001).
155. Bakker, A.B., Wu, J., Phillips, J.H. & Lanier, L.L. NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. Hum. Immunol. 61, 18-27 (2000).
156. Campbell, K.S. & Colonna, M. Human natural killer cell receptors and signal transduction. Int. Rev. Immunol. 20, 333-370 (2001).
157. Lanier, L.L. Natural killer cell receptor signaling. Curr. Opin. Immunol. 15, 308-314 (2003).
158. Cerwenka, A. & Lanier, L.L. Ligands for natural killer cell receptors: redundancy or specificity. Immunol. Rev. 181, 158-169 (2001).
159. Radaev, S. & Sun, P.D. Structure and function of natural killer cell surface receptors. Annu. Rev. Biophys. Biomol. Struct. 32, 93-114 (2003).
160. Versteeg, R. NK cells and T cells: mirror images? Immunol. Today 13, 244-247 (1992).
161. Farrell, H.E. & Davis-Poynter, N.J. From sabotage to camouflage: viral evasion of cytotoxic T lymphocyte and natural killer cell-mediated immunity. Semin. Cell Dev. Biol. 9, 369-378 (1998).
162. Lorenzo, M.E., Ploegh, H.L. & Tirabassi, R.S. Viral immune evasion strategies and the underlying cell biology. Semin. Immunol. 13, 1-9 (2001).
163. Basta, S. & Bennink, J.R. A survival game of hide and seek: cytomegaloviruses and MHC class I antigen presentation pathways. Viral Immunol. 16, 231-242 (2003).
164. + T lymphocytes. Cell 77, 525-535 (1994).
165. Fruh, K. et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 375, 415-418 (1995).
166. Park, B. et al. Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. Immunity 20, 71-85 (2004).
167. Wiertz, E.J. et al. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84, 769-779 (1996).
168. Ljunggren, H.G. & Karre, K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today 11, 237-244 (1990).
169. Brennan, J., Mahon, G., Mager, D.L., Jefferies, W.A. & Takei, F. Recognition of class I major histocompatibility complex molecules by Ly-49: specificities and domain interactions. J. Exp. Med. 183, 1553-1559 (1996).
170. Smith, H.R. et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc. Natl. Acad. Sci. USA 99, 8826-8831 (2002).
171. Voigt, V. et al. Murine cytomegalovirus m157 mutation and variation leads to immune evasion of natural killer cells. Proc. Natl. Acad. Sci. USA 100, 13483-13488 (2003).
172. Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727-729 (1999).
173. Diefenbach, A., Jamieson, A.M., Liu, S.D., Shastri, N. & Raulet, D.H. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat. Immunol. 1, 119-126 (2000).
174. Sutherland, C.L., Chalupny, N.J. & Cosman, D. The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions. Immunol. Rev. 181, 185-192 (2001).
175. Carayannopoulos, L.N., Naidenko, O.V., Fremont, D.H. & Yokoyama, W.M. Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J. Immunol. 169, 4079-4083 (2002).
176. Long, E.O. Tumor cell recognition by natural killer cells. Semin. Cancer Biol. 12, 57-61 (2002).
177. Diefenbach, A. & Raulet, D.H. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol. Rev. 188, 9-21 (2002).
178. Cerwenka, A. & Lanier, L.L. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61, 335-343 (2003).
179. Groh, V., Wu, J., Yee, C. & Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734-738 (2002).
180. Salih, H.R. et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102, 1389-1396 (2003).
181. Bendelac, A., Rivera, M.N., Park, S.H. & Roark, J.H. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol. 15, 535-562 (1997).
182. Taniguchi, M. & Nakayama, T. Recognition and function of Vα14 NKT cells. Semin. Immunol. 12, 543-550 (2000).
183. Zeng, Z. et al. Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove. Science 277, 339-345 (1997).
184. Kawano, T. et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278, 1626-1629 (1997).
185. Zhou, D. et al. Lysosomal glycosphingolipid recognition by NKT cells. Science, published online 11 November 2004 (doi: 10.1126/science.1103440)
186. Brigl, M., Bry, L., Kent, S.C., Gumperz, J.E. & Brenner, M.B. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 4, 1230-1237 (2003).
187. Teixeira, H.C. & Kaufmann, S.H. Role of NK1.1+ cells in experimental listeriosis. NK1+ cells are early IFN-gamma producers but impair resistance to Listeria monocytogenes infection. J. Immunol. 152, 1873-1882 (1994).
188. H2 response and in immunoglobulin E production. Science 270, 1845-1847 (1995).
189. Biron, C.A. & Brossay, L. NK cells and NKT cells in innate defense against viral infections. Curr. Opin. Immunol. 13, 458-464 (2001).
190. Biron, C.A., Nguyen, K.B., Pien, G.C., Cousens, L.P. & Salazar-Mather, T.P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17, 189-220 (1999).
191. Steinman, R.M. Some interfaces of dendritic cell biology. APMIS 111, 675-697 (2003).
192. Green, D.R. & Webb, D.R. Saying the 'S' word in public. Immunol. Today 14, 523-525 (1993).
193. Shevach, E.M. Regulatory T cells in autoimmmunity*. Annu. Rev. Immunol. 18, 423-449 (2000).
194. + T cells. Adv. Immunol. 81, 331-371 (2003).
195. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151-1164 (1995).
196. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061 (2003).
197. + regulatory T cells. Nat. Immunol. 4, 330-336 (2003).
198. + T regulatory cells. Nat. Immunol. 4, 337-342 (2003).
199. + regulatory T cells. Curr. Opin. Immunol. 16, 203-208 (2004).
200. Ramsdell, F. Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 19, 165-168 (2003).
201. Gambineri, E., Torgerson, T.R. & Ochs, H.D. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr. Opin. Rheumatol. 15, 430-435 (2003).
202. Chatenoud, L., Salomon, B. & Bluestone, J.A. Suppressor T cells-they're back and critical for regulation of autoimmunity! Immunol. Rev. 182, 149-163 (2001).
203. Berzins, S.P., Venanzi, E.S., Benoist, C. & Mathis, D. T-cell compartments of prediabetic NOD mice. Diabetes 52, 327-334 (2003).
204. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182, 18-32 (2001).
205. Karim, M., Bushell, A.R. & Wood, K.J. Regulatory T cells in transplantation. Curr. Opin. Immunol. 14, 584-591 (2002).
206. Rouse, B.T. & Suvas, S. Regulatory cells and infectious agents: detentes cordiale and contraire. J. Immunol. 173, 2211-2215 (2004).
207. + regulatory T cells control Leishmania major persistence and immunity. Nature 420, 502-507 (2002).
208. Roncarolo, M.G., Bacchetta, R., Bordignon, C., Narula, S. & Levings, M.K. Type 1 T regulatory cells. Immunol. Rev. 182, 68-79 (2001).
209. H2-inducing cytokines. J. Exp. Med. 195, 603-616 (2002).
210. Malek, T.R. The main function of IL-2 is to promote the development of T regulatory cells. J. Leukoc. Biol. 74, 961-965 (2003).
211. + immunoregulatory cells. J. Immunol. 167, 1137-1140 (2001).
212. Thornton, A.M. & Shevach, E.M. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J. Immunol. 164, 183-190 (2000).
213. + T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J. Exp. Med. 197, 111-119 (2003).
214. + regulatory T cells is mediated by cell surface-bound transforming growth factor β. J. Exp. Med. 194, 629-644 (2001).
215. + regulatory T cell activity in both humans and mice. J. Immunol. 172, 834-842 (2004).
216. + T cell-mediated suppression by dendritic cells. Science 299, 1033-1036 (2003).
217. Sharpe, A.M. & Freeman, G.J. The B7-CD28 superfamily. Nat. Rev. Immunol. 2, 116-126 (2002).
218. Carreno, B.M. & Collins, M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20, 29-53 (2002).
219. Alegre, M.L., Frauwirth, K.A. & Thompson, C.B. T-cell regulation by CD28 and CTLA-4. Nat. Rev. Immunol. 1, 220-228 (2001).
220. Chambers, C.A., Kuhns, M.S., Egen, J.G. & Allison, J.P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19, 565-594 (2001).
221. Egen, J.G. & Allison, J.P. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 16, 23-35 (2002).
222. Pentcheva-Hoang, T., Egen, J.G., Wojnoonski, K. & Allison, J.P. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 21, 401-413 (2004).
223. Tseng, S.Y. et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193, 839-846 (2001).
224. Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141-151 (1999).
225. Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261-268 (2001).
226. Chen, L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4, 336-347 (2004).
227. Dong, C., Nurieva, R.I. & Prasad, D.V. Immune regulation by novel costimulatory molecules. Immunol. Res. 28, 39-48 (2003).
228. Newton, K. & Strasser, A. Cell death control in lymphocytes. Adv. Immunol. 76, 179-226 (2000).
229. Surh, C.D. & Sprent, J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 372, 100-103 (1994).
230. Palmer, E. Negative selection-clearing out the bad apples from the T-cell repertoire. Nat. Rev. Immunol. 3, 383-391 (2003).
231. Defrance, T., Casamayor-Palleja, M. & Krammer, P.H. The life and death of a B cell. Adv. Cancer Res. 86, 195-225 (2002).
232. Jankovic, M., Casellas, R., Yannoutsos, N., Wardemann, H. & Nussenzweig, M.C. RAGs and regulation of autoantibodies. Annu. Rev. Immunol. 22, 485-501 (2004).
233. MacLennan, I.C. Germinal centers. Annu. Rev. Immunol. 12, 117-139 (1994).
234. Ahmed, R. & Gray, D. Immunological memory and protective immunity: understanding their relation. Science 272, 54-60 (1996).
235. + effector and memory T cell generation. Nat. Immunol. 4, 835-842 (2003).
236. Fisher, G.H. et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81, 935-946 (1995).
237. Chan, F.K. et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288, 2351-2354 (2000).
238. Croft, M. Costimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3, 609-620 (2003).
239. Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708-712 (1999).
240. + T cell memory. Science 297, 2060-2063 (2002).
241. + T lymphocytes. Nature 421, 852-856 (2003).
242. Sun, J.C. & Sevan, M.J. Cutting edge: long-lived CD8 memory and protective immunity in the absence of CD40 expression on CD8 T cells. J. Immunol. 172, 3385-3389 (2004).
243. Sun, J.C. & Bevan, M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300, 339-342 (2003).
244. Shedlock, D.J. & Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300, 337-339 (2003).
245. + T-cell response. Nat. Rev. Immunol. 4, 595-602 (2004).
246. Butcher, E.C. & Picker, L.J. Lymphocyte homing and homeostasis. Science 272, 60-66 (1996).
247. Cyster, J.G. Chemokines and cell migration in secondary lymphoid organs. Science 286, 2098-2102 (1999).
248. von Andrian, U.H. & Mackay, C.R. T-cell function and migration. Two sides of the same coin. N. Engl. J. Med. 343, 1020-1034 (2000).
249. Mackay, C.R. Chemokines: immunology's high impact factors. Nat. Immunol. 2, 95-101 (2001).
250. Murphy, P.M. Chemokines. in Fundamental Immunology (ed. Paul, W.E.) 801-840 (Lippincott, Williams, and Wilkins, Philadelphia, 2003).
251. Forster, R. et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99, 23-33 (1999).
252. Sallusto, F., Mackay, C.R. & Lanzavecchia, A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18, 593-620 (2000).
253. Forster, R. et al. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 87, 1037-1047 (1996).
254. Ansel, K.M. et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406, 309-314 (2000).
255. Cyster, J.G. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu. Rev. Immunol. published online 11 October 2004 (doi: 10.1146/annurev.immunol.23.021704.115628)
256. Mora, J.R. et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 424, 88-93 (2003).
257. Kim, C.H., Nagata, K. & Butcher, E.C. Dendritic cells support sequential reprogramming of chemoattractant receptor profiles during naive to effector T cell differentiation. J. Immunol. 171, 152-158 (2003).
258. Iwata, M. et al. Retinoic Acid imprints gut-homing specificity on T cells. Immunity 21, 527-538 (2004).
259. Berger, E.A., Murphy, P.M. & Farber, J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17, 657-700 (1999).
260. Horuk, R. et al. A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 261, 1182-1184 (1993).
261. Murphy, P.M. Viral exploitation and subversion of the immune system through chemokine mimicry. Nat. Immunol. 2, 116-122 (2001).
262. Altman, J.D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96 (1996).
263. Reijonen, H. & Kwok, W.W. Use of HLA class II tetramers in tracking antigen-specific T cells and mapping T-cell epitopes. Methods 29, 282-288 (2003).
264. Meidenbauer, N., Hoffmann, T.K. & Donnenberg, A.D. Direct visualization of antigen-specific T cells using peptide-MHC-class I tetrameric complexes. Methods 31, 160-171 (2003).
265. Monks, C.R., Freiberg, B.A., Kupfer, H., Sciaky, N. & Kupfer, A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395, 82-86 (1998).
266. Wulfing, C., Sjaastad, M.D. & Davis, M.M. Visualizing the dynamics of T cell activation: intracellular adhesion molecule 1 migrates rapidly to the T cell/B cell interface and acts to sustain calcium levels. Proc. Natl. Acad. Sci. USA 95, 6302-6307 (1998).
267. Grakoui, A. et al. The immunological synapse: a molecular machine controlling T cell activation. Science 285, 221-227 (1999).
268. Bromley, S.K. et al. The immunological synapse. Annu. Rev. Immunol. 19, 375-396 (2001).
269. Kupfer, A. & Kupfer, H. Imaging immune cell interactions and functions: SMACs and the Immunological Synapse. Semin. Immunol. 15, 295-300 (2003).
270. Davis, M.M. et al. Dynamics of cell surface molecules during T cell recognition. Annu. Rev. Biochem. 72, 717-742 (2003).
271. Reinhardt, R.L., Khoruts, A., Merica, R., Zell, T. & Jenkins, M.K. Visualizing the generation of memory CD4 T cells in the whole body. Nature 410, 101-105 (2001).
272. Stoll, S., Delon, J., Brotz, T.M. & Germain, R.N. Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science 296, 1873-1876 (2002).
273. Cahalan, M.D., Parker, I., Wei, S.H. & Miller, M.J. Two-photon tissue imaging: seeing the immune system in a fresh light. Nat. Rev. Immunol. 2, 872-880 (2002).
274. Miller, M.J., Wei, S.H., Parker, I. & Cahalan, M.D. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. Science 296, 1869-1873 (2002).
275. Bousso, P., Bhakta, N.R., Lewis, R.S. & Robey, E. Dynamics of thymocyte-stromal cell interactions visualized by two-photon microscopy. Science 296, 1876-1880 (2002).
276. + T cell priming by dendritic cells in intact lymph nodes. Nat. Immunol. 4, 579-585 (2003).
277. Mempel, T.R., Henrickson, S.E. & Von Andrian, U.H. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427, 154-159 (2004).
278. Waldmann, T.A. Immunotherapy: past, present and future. Nat. Med. 9, 269-277 (2003).
279. Hacein-Bey-Abina, S. et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346, 1185-1193 (2002).
280. Hacein-Bey-Abina, S. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419 (2003).
281. Chinen, J. & Puck, J.M. Successes and risks of gene therapy in primary immunodeficiencies. J. Allergy. Clin. Immunol. 113, 595-603; quiz 604 (2004).
282. Van Der Bruggen, P. et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188, 51-64 (2002).
283. Pardoll, D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807-839 (2003).
284. Rosenberg, S.A. Shedding light on immunotherapy for cancer. N. Engl. J. Med. 350, 1461-1463 (2004).
285. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 20, 107-118 (2004).
286. Egen, J.G., Kuhns, M.S. & Allison, J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3, 611-618 (2002).
287. Hodi, F.S. et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA 100, 4712-4717 (2003).
288. Phan, G.Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100, 8372-8377 (2003).
289. Herzenberg, L.A., Black, S.J. & Herzenberg, L.A. Regulatory circuits and antibody responses. Eur. J. Immunol. 10, 1-11 (1980).
290. Germain, R.N. The art of the probable: system control in the adaptive immune system. Science 293, 240-245 (2001).
291. Gett, A.V. & Hodgkin, P.D. A cellular calculus for signal integration by T cells. Nat. Immunol. 1, 239-244 (2000).
292. Brenner, S. End of the interlude? Nat. Biotechnol. 22, 1191 (2004).
293. Amsen, D. et al. Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell 117, 515-526 (2004).
294. + T cells. Immunity 19, 549-559 (2003).
295. Akira, S. & Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499-511 (2004).
296. Vivier, E. & Anfossi, N. Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat. Rev. Immunol. 4, 190-198 (2004).
297. Bottino, C., Moretta, L., Pende, D., Vitale, M. & Moretta, A. Learning how to discriminate between friends and enemies, a lesson from Natural Killer cells. Mol. Immunol. 41, 569-575 (2004).
298. Grossman, W.J. et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21, 589-601 (2004).